BI 1245.110
Chronic heart failure with preserved ejection fraction. Phase III
BI 1245.121
Chronic heart failure with reduced ejection fraction. Phase III
DELIVER
Chronic heart failure with preserved ejection fraction. Phase III
VOYAGER
Risk of thrombotic vascular events. Phase III
AUGUSTUS
Atrial fibrillation and acute coronary syndrome. Phase IV
ATLAS
Acute coronary syndrome. Phase ii
CANTOS
Infarction and vascular inflammation. Phase III
CHARISMA
Antiplatelet cardiovascular prevention. Phase III
CRESCENDO
Cardiovascular risk. Phase III
CSPP
Hypertension. Phase IV
CVT1
Cardiovascular diagnosis. Phase III
CVT2
Ischemic markers. Phase III
DAPA-HF
Chronic heart failure with reduced ejection fraction. Phase III
EUCLID
Peripheral vascular disease. Phase IIIb
GEMINI
Cardiovascular event. Phase III
OASIS
Acute ischemia. Phase III
ODDYSEY
Acute coronary syndrome. Phase IIIb
PARADIGM
Heart failure. Phase III
PEGASUS
Myocardial infarction and secondary prevention. Phase III
STEP-WISE
Heart failure. Phase IIb
THEMIS
Secondary prevention of heart attack. Phase IIIb
There are no active studies at this time
AP611074 CT4
Genital condyloma. Phase ii
SCORED
Diabetes and kidney failure. Phase III
VERTIS
Diabetes and cardiovascular risk. Phase III
DAPA CK3
Diabetes and kidney failure. Phase III
DAPA CK4
Diabetes and kidney failure. Phase III
AFICIONADO
Diabetes. Phase IV
ABBVIE
Diabetes and diabetic nephropathy. Phase III
BCB109
Diabetes. Phase III
BC21713
Diabetes. Phase III
BI1218.18
Diabetes. Phase III
BI1245.9
Diabetes. Phase ii
BI1245.10
Diabetes. Phase ii
B1261007
Diabetic nephropathy. Phase III
CACZ
Diabetes. Phase IIb
CLAF 2308
Diabetes. Phase III
CLAF 2310
Diabetes. Phase III
CLAF 2338
Diabetes. Phase III
CLAF 23137
Poorly controlled diabetes with kidney disease. Phase III
CREDENCE
Diabetic nephropathy. Phase III
D1680C0002
Diabetes. Phase IIIb
D1680C0003
Diabetes. Phase IV
DAPA10
Diabetes. Phase IIIb
DECLARE
Diabetes. Phase III
DIA 3008
Diabetes. Phase III
DIA 3011
Diabetes. Phase III
DIA 4003
Diabetes and cardiovascular risk. Phase III
ELIXA
Diabetes and cardiovascular risk. Phase III
EXCSEL
Diabetes and cardiovascular risk. Phase III
FOREST
Diabetes. Phase III
GETGOAL X
Diabetes. Phase III
HARMONY
Diabetes with cardiovascular event. Phase III / IV
IMAGINE 2
Diabetes. Phase III
M11-352
Diabetes and diabetic nephropathy. Phase III
MK-018
Diabetes and cardiovascular risk. Phase III
MK0431-845
Diabetes. Phase III
MK0431-848
Diabetes. Phase III
MK-8835-001
Diabetes and diabetic nephropathy. Phase III
MK-8835-005
Diabetes. Metformin fails. Phase III
NN-95353626
Diabetes. Phase IIIa
ORIGIN
Diabetes and cardiovascular prevention. Phase III
RECAP
Diabetes. Phase III
SAVOR
Diabetes and cardiovascular risk. Phase III
SERENADE
Diabetes. Phase III
TECOS
Diabetes. Phase III
HIBISCUS I
Ulcerative colitis Phase II / III
HIBISCUS II
Ulcerative colitis Phase III
RLM-MD-02
Diabetic gastroparesis. Phase III
RLM-MD-03
Diabetic gastroparesis. Extension study of the RLM-MD-02. Phase III
RLM-MD-04
Diabetic gastroparesis. Phase III
TAKEDA 3030
Ulcerative colitis and Crohn's disease. Phase III
TAKEDA 3031
Ulcerative colitis and Crohn's disease. Phase III
ESTETRA
Hot flushes. Estetrol and placebo
205270
Anemia associated with chronic kidney disease
AKEBIA 14
Anemia and kidney failure. Phase III
AKEBIA 15
Anemia and kidney failure. Phase III
ASCEND
Anemia and kidney failure. Phase III
CREDENCE
Anemia and kidney failure. Phase III
OLYMPUS
Anemia and kidney failure. Phase III
PODOCYTE
Focal and segmental glomerulosclerosis. Phase III
DAPA CKD
Chronic kidney failure and proteinuria. Phase III
208657
COPD characterized by frequent exacerbations and levels of EOSINOPHILS. Phase III
BOREAS
COPD with eosinophilia. Phase III
HZA
Asthma in pediatric patients. Phase III
PEARL
COPD. Phase III
201378
Bronchial asthma. Phase III
ACD113874
COPD. Phase III
BORA
Severe bronchial asthma Phase III
CALIMA
Uncontrolled asthma Phase III
CHIESI
COPD. Phase III
CQAB149B2401
COPD. Phase III
CQVA
Moderate to severe COPD. Phase III
CTT
COPD. Phase III
D3250C00018
Uncontrolled asthma Phase III
DYNAGITO
COPD. Phase III
HZA
Asthma in children. Phase III
HZC113782
COPD. Phase II
LABA
Bronchial asthma. Phase III
MEDIVECTOR
Uncomplicated influenza. Phase III
SAS115358
Asthma in children. Phase IIb
SOPHOS
COPD. Phase III
SUMMIT
COPD. Phase III
TERRANOVA
Severe bronchial asthma Phase III
VESTRI
Asthma in children. Phase IV
There are no active studies at this time
AMGEM 20110142
Osteoporosis. Phase III
AMGEN 337
Osteoporosis. Phase III
CZOL446M2309
Osteoporosis. Phase III
GHDW
Osteoporosis. Phase IV
RADIUS
Osteoporosis. Phase II
CONTRAST 1
Rheumatoid arthritis. Phase III
CONTRAST 3
Rheumatoid arthritis. Phase III
CONTRAST X
Contrast 1 and Contrast 3 Extension Study
CREDO 4
Extension of the CREDO 2 and CREDO 3 studies. Phase III
JADY
Rheumatoid arthritis. Phase III
OLE
Rheumatoid arthritis. Phase II
CREDO 2
Rheumatoid arthritis for patients with inadequate response to methotrexate. Phase III
ANDES
Rheumatoid arthritis. Phase II
CREDO 3
Rheumatoid arthritis for patients with inadequate response to TNF inhibitors. Phase III
DRIVE
DVT Prophylaxis enti II anti X. Phase II
HIP 1
Hip replacement. Phase III
HIP 2
Hip fracture. Phase III
EFC10571
Knee replacement. Phase III
JADV
Rheumatoid arthritis. Phase III
JADZ
Rheumatoid arthritis. Phase III
KOWA
Hypertriglyceridaemia. Phase III
CLEAR
Hypertriglyceridaemia. Phase III
ODDYSEY
Dyslipidemia and acute myocardial infarction. Phase III
READY 1.
Phase 3 Clinical Study.
Objective To evaluate the efficacy and safety of CUSA-081 (Reteplase) vs Alteplase vs placebo in the treatment of dysfunction of CVAD (Central Catheters)
ATHENA
Atrial fibrillation Phase III
BOREALIS
Atrial fibrillation Phase III
HOKUSAI
TVP/EP. Phase III
MARINER
Thromboembolic disease. Phase III
ROCKET
Atrial fibrillation Phase III
There are no active studies at this time
AMEERA-5
Advanced breast cancer. Amcanestrant (SAR439859) plus Plabociclib compared with treatment of ER (+), HER (-) breast cancer patients who have not received any prior systemic antineoplastic therapy for advanced disease.
There are no active studies at this time
